The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study

Objective: To evaluate the performance of total maximum sequential organ failure assessment (SOFA) score and a derived measure, delta SOFA (total maximum SOFA score minus admission total SOFA) as a descriptor of multiple organ dysfunction/failure in intensive care. Design: Prospective, multicentre and multinational study. Setting: Forty intensive care units (ICUs) from Australia, Europe, North and South America. Patients: Data on 1,449 patients, evaluated at admission and then consecutively every 24 h until ICU discharge (11,417 records) during May 1995. Excluded from data collection were all patients with a length of stay in the ICU less than 2 days following uncomplicated scheduled surgery. Main outcome measure: Survival status at ICU discharge. Interventions: The collection of raw data necessary for the computation of a SOFA score on admission and then every 24 h, and basic demographic and clinical statistics. Measurements and main results: Mean total maximum SOFA score presented a very good correlation to ICU outcome, with mortality rates ranging from 3.2 % in patients without organ failure to 91.3 % in patients with failure of all the six organs analysed. A maximum score was reached 1.1 ± 0.2 days after admission for all the organ systems analysed. The total maximum SOFA score presented an area under the ROC curve of 0.847 (SE 0.012), which was significantly higher than any of its individual components. The cardiovascular score (odds ratio 1.68) was associated with the highest relative contribution to outcome. No independent contribution could be demonstrated for the hepatic score. No significant interactions were found. Principal components analysis demonstrated the existence of a two-factor structure that became clearer when analysis was limited to the presence or absence of organ failure (SOFA score ≥ 3 points) during the ICU stay. The first factor comprises respiratory, cardiovascular and neurological systems and the second coagulation, hepatic and renal systems. Delta SOFA also presented a good correlation to outcome. The area under the receiver operating characteristic (ROC) curve was 0.742 (SE 0.017) for delta SOFA, lower than the total maximum SOFA score or admission total SOFA score. The impact of delta SOFA on prognosis remained significant after correction for admission total SOFA. Conclusions: The results show that total maximum SOFA score and delta SOFA can be used to quantify the degree of dysfunction/failure already present on ICU admission, the degree of dysfunction/failure that appears during the ICU stay and the cumulative insult suffered by the patient. These properties make it a good instrument to be used in the evaluation of organ dysfunction/failure.

[1]  G. Bailey,et al.  Sequential System Failure after Rupture of Abdominal Aortic Aneurysms: An Unsolved Problem in Postoperative Care , 1973, Annals of surgery.

[2]  D. Kleinbaum,et al.  Applied Regression Analysis and Other Multivariate Methods , 1978 .

[3]  R. L. Fulton,et al.  Multiple system organ failure. The role of uncontrolled infection. , 1980, Archives of surgery.

[4]  E. Faist,et al.  MULTIPLE ORGAN FAILURE IN POLY-TRAUMA PATIENTS , 1982 .

[5]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[6]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[7]  W. Marshall,et al.  The natural history of major burns with multiple subsystem failure. , 1983, The Journal of trauma.

[8]  E. Faist,et al.  Multiple organ failure in polytrauma patients. , 1983, The Journal of trauma.

[9]  J. D. Smith,et al.  Multiple organ system failure and infection in adult respiratory distress syndrome. , 1983, Annals of internal medicine.

[10]  S. Hoffman,et al.  Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. , 1984, The New England journal of medicine.

[11]  E. Draper,et al.  Prognosis in Acute Organ‐System Failure , 1985, Annals of surgery.

[12]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[13]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[14]  R. Chang,et al.  Predicting outcome among intensive care unit patients using computerised trend analysis of daily Apache II scores corrected for organ system failure , 1988, Intensive Care Medicine.

[15]  D. K. Williams,et al.  Assessing hospital-associated deaths from discharge data. The role of length of stay and comorbidities. , 1988, JAMA.

[16]  R. Chang,et al.  INDIVIDUAL OUTCOME PREDICTION MODELS FOR INTENSIVE CARE UNITS , 1989, The Lancet.

[17]  R. Dennis,et al.  Risk factors for multiorgan failure: a case-control study. , 1991, The Journal of trauma.

[18]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[19]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[20]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[21]  P. Clyburn,et al.  The Riyadh Intensive Care Program applied to a mortality analysis of a teaching hospital intensive care unit , 1992, Anaesthesia.

[22]  Tran Dd,et al.  Evaluation of severity in patients with acute pancreatitis. , 1992 .

[23]  M. Cuesta,et al.  Evaluation of severity in patients with acute pancreatitis. , 1992, The American journal of gastroenterology.

[24]  W. Knaus,et al.  Reliability of a measure of severity of illness: acute physiology of chronic health evaluation--II. , 1992, Journal of clinical epidemiology.

[25]  E. Deitch,et al.  Multiple organ failure. Pathophysiology and potential future therapy. , 1992, Annals of surgery.

[26]  S. Lemeshow,et al.  Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. , 1993, JAMA.

[27]  J. Singer,et al.  A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. , 1993, Chest.

[28]  D. Wagner,et al.  Glasgow Coma Scale score in the evaluation of outcome in the intensive care unit: Findings from the Acute Physiology and Chronic Health Evaluation III study , 1993, Critical care medicine.

[29]  R. Bone.  Guidelines for the Use of Innovative Therapies in Sepsis , 1993 .

[30]  C J Fisher,et al.  The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. , 1993, JAMA.

[31]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[32]  D. Wagner,et al.  Daily prognostic estimates for critically ill adults in intensive care units: Results from a prospective, multicenter, inception cohort analysis , 1994, Critical care medicine.

[33]  S Lemeshow,et al.  Mortality probability models for patients in the intensive care unit for 48 or 72 hours: A prospective, multicenter study , 1994, Critical care medicine.

[34]  J. Dhainaut,et al.  Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial , 1994 .

[35]  J Rogers,et al.  Use of daily Acute Physiology and Chronic Health Evaluation (APACHE) II scores to predict individual patient survival rate , 1994, Critical care medicine.

[36]  M. Kollef.  The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis. , 1994, Chest.

[37]  W. Knaus,et al.  What Determines Prognosis in Sepsis? Evidence for a Comprehensive Individual Patient Risk Assessment Approach to the Design and Analysis of Clinical Trials , 1994 .

[38]  W. Sibbald,et al.  Round table conference on clinical trials for the treatment of sepsis. , 1995, Critical care medicine.

[39]  G. Grégoire,et al.  Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? , 1995, Journal of clinical epidemiology.

[40]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[41]  J. Marshall,et al.  Should morbidity replace mortality as an endpoint for clinical trials in intensive care? , 1995, The Lancet.

[42]  S Lemeshow,et al.  Customized probability models for early severe sepsis in adult intensive care patients. Intensive Care Unit Scoring Group. , 1995, JAMA.

[43]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[44]  M. Glauser,et al.  International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. , 1996, Critical care medicine.

[45]  H. Verbrugh,et al.  Delta APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. , 1996, The Journal of infectious diseases.

[46]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[47]  R. Auckenthaler,et al.  Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. , 1996, American journal of respiratory and critical care medicine.

[48]  William A. Knaus,et al.  Severity Stratification and Outcome Prediction for Multisystem Organ Failure and Dysfunction , 1996, World Journal of Surgery.

[49]  C. Sprung,et al.  The spectrum of septic encephalopathy. Definitions, etiologies, and mortalities. , 1996, JAMA.

[50]  Back to the drawing board. , 1996, Critical care medicine.

[51]  S Lemeshow,et al.  The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. , 1996, JAMA.

[52]  W. Buurman,et al.  TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL; , 1996, Shock.

[53]  K. Rowan.  The reliability of case mix measurement in intensive care , 1996 .

[54]  J. Carlet,et al.  INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.

[55]  G. Bernard,et al.  The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. , 1997, The New England journal of medicine.

[56]  H. Bruining,et al.  p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial , 1997 .

[57]  Stanley Lemeshow,et al.  The Logistic Organ Dysfunction System , 1997 .

[58]  Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. , 1997, JAMA.

[59]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[60]  G. Bernard.  Quantification of organ dysfunction: seeking standardization. , 1998, Critical care medicine.

[61]  OLAND,et al.  TREATMENT OF SEPTIC SHOCK WITH THE TUMOR NECROSIS FACTOR RECEPTOR : Fc FUSION PROTEIN C , 2000 .